Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Explore the challenges of identifying and reaching rare disease patient populations throughout clinical development and commercialization · See how genomic, phenotypic, claims and EHR data can uncover patients, disease characteristics and healthcare journeys · Understand how patient-level insights can support cohort identification, clinical trial enrollment and clinical development decisions · Learn how insights generated across the therapy ... Explore the challenges of identifying and reaching rare disease patient populations throughout clinical development and commercialization · See how genomic, phenotypic, claims and EHR data can uncover patients, disease characteristics and healthcare journeys · Understand how patient-level insights can support cohort identification, clinical trial enrollment and clinical development decisions · Learn how insights generated across the therapy lifecycle can guide future development programs and support continuous discovery Biotech 1623 Clinical Trials 2376 Drug Discovery & Development 1625 Life Science 4693 Patient Recruitment & Retention 417 Pharma 2927 · Jump to every webinar tagged with a keyword from this one. Clinical Data Clinical Development Clinical Research Drug Development Genomic Data Genomics Patient Population Patient Recruitment Rare Diseases/Orphan Drugs Real-World Data Therapeutic Areas Join this webinar to explore how patient population data can improve rare disease patient identification and trial enrollment. Colleen Caleshu is a Clinician-Scientist Leader and Genetic Counselor with more than 23 years of experience in genomic medicine and real-world data, including over a decade collaborating with rare disease biopharma organizations. As Senior Director of Translational Research at GeneDx, she leverages GeneDx Infinity, the world’s largest clinically interpreted genomic dataset, to lead research and real-world evidence strategies that support biopharma partners across evidence generation, study design and clinical trial-enabling patient cohort development.
Original title: “Use Patient Population Data to Improve Therapy Lifecycle Decisions - Xtalks”
The FDA’s Rare Disease Framework aims to speed rare disease drug development using flexible evidence standards. Read more here. Oct 14, 2026, 1:16 PM ETIntellia Therapeutics, Inc. (NTLA) Stock, BEAM Stock, RARE Stock, SRPT Stock, BBIO Stock, IONS Stock, RCKT Stock, KRYS StockBy: Jonathan Block, SA News Editor · The US FDA has launched a Rare Disease Framework Initiative that is designed to reflect "the realities of rare disease drug development by considering the nuances of each disease, patient needs, product type and the evidence that can be realistically generated in small
Original title: “FDA unveils rare disease initiative to enhance therapy development | Seeking Alpha”
Today represents an extraordinary inflection point for our community. This morning, the FDA announced it would undertake a new initiative to take a fresh look at how it approaches rare […]
Original title: “FDA Introduces a New Framework for Rare Disease Review”
In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.
Original title: “Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit”
The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.
Original title: “FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development”
Conclusions: In the DISRUPT PAD ... disease treated with IVL had low rates of repeat revascularization and major amputation, and had significant improvement in quality of life. These results support the long-term safety and effectiveness of IVL in the treatment of challenging patients with complex calcified BTK lesions. Adjunctive Transdermal Continuous Oxygen Therapy Accelerates Surgical Wound Healing After Lower Extremity Revascularization: A Randomized Clinical Trial Presented ... Conclusions: In the DISRUPT PAD BTK II study, patients with heavily calcified below-the-knee disease treated with IVL had low rates of repeat revascularization and major amputation, and had significant improvement in quality of life. These results support the long-term safety and effectiveness of IVL in the treatment of challenging patients with complex calcified BTK lesions. Adjunctive Transdermal Continuous Oxygen Therapy Accelerates Surgical Wound Healing After Lower Extremity Revascularization: A Randomized Clinical Trial Presented by Khanjan Nagarsheth, MD, MBA /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and... Transdermal continuous oxygen therapy (TCOT) delivers concentrated oxygen directly to the wound environment; however, its effectiveness in accelerating healing of postoperative vascular surgical incisions has not previously been evaluated in a randomized clinical trial. This prospective, single-center randomized trial evaluated 118 adults undergoing elective lower extremity revascularization for atherosclerotic peripheral arterial disease. Bringing together experts in vascular medicine, interventional cardiology, interventional radiology, and vascular surgery, the Foundation provides multidisciplinary education designed to improve patient care and advance innovative therapies for vascular disease worldwide. To learn more about the VIVA Foundation, visit https://viva-foundation.org/. ... The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, today... The VIVA Foundation will spotlight the latest advances in vascular medicine as 26 clinical trials are presented during The VEINS and VIVA 2026,...
Original title: “Late-Breaking Clinical Trial Results Announced at VIVA 2026”
Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.”
Original title: “Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled”
Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.
Original title: “Verastem cancer drug shows early promise in small study”
Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s claims.
Original title: “CVS to pay $315M to settle opioid prescribing allegations”
Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and Cassava, the FTC alleges.
Original title: “‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban”
The layoffs across GSK’s Belgium sites come on the heels of the pharma’s planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.
Original title: “GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentum”